Physician Style Crucial in Enrolling Black Men in Clinical Trials

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 5
Volume 11
Issue 5

WASHINGTON-Despite the high rate of cancer among black men in the United States, their participation in clinical trials is low. The interaction between these patients and their physicians affects willingness to enroll in trials, Dawn L. Riddle, PhD, of the H. Lee Moffitt Cancer Center, reported at the 8th Biennial Symposium on Minorities, the Medically Underserved, and Cancer. She described pilot data indicating that when physicians go beyond simply imparting legal and medical information about the trial and make a strategic effort to answer the patient’s concerns, discover any barriers that impede his participation, and remove those barriers, black men are more likely to consent to participate.

WASHINGTON—Despite the high rate of cancer among black men in the UnitedStates, their participation in clinical trials is low. The interaction betweenthese patients and their physicians affects willingness to enroll in trials,Dawn L. Riddle, PhD, of the H. Lee Moffitt Cancer Center, reported at the 8thBiennial Symposium on Minorities, the Medically Underserved, and Cancer. Shedescribed pilot data indicating that when physicians go beyond simply impartinglegal and medical information about the trial and make a strategic effort toanswer the patient’s concerns, discover any barriers that impede hisparticipation, and remove those barriers, black men are more likely to consentto participate.

Recent Videos
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content